Dr. Lue is Professor and Emil Tanagho Endowed Chair in Clinical Urology at the University of California San Francisco and medical director of the Knuppe Molecular Urology Laboratory. Dr. Lue is an internationally recognized expert on treatment of male sexual dysfunction and a pioneer in surgical methods to treat Peyronie’s disease and priapism. His research team proved that PDE5 inhibitors enhance erection in animals, providing the scientific basis for Viagra, Levitra and Cialis. He is also an expert on incontinence and developed the first animal model of female stress urinary incontinence, now used widely to study potential treatments. He is co-inventor of the sacral stimulation method of treating urge incontinence, the technology underlying Medtronic’s Interstim product line. Dr. Lue graduated with highest honors from the Kaohsiung Medical University in Taiwan and completed his urologic training at the State University of New York Downstate Medical Center. He has authored or co-authored twelve books and more than 500 scientific publications. He is the recipient of numerous honors, including the Gold Cystoscope Award and Presidential Citation from the American Urological Association and an award for most innovative research from the American Foundation of Urologic Diseases, Valentine Medal from New York Academy of Medicine, MERIT Award from NIDDK, NIH, and America's Top Doctor (on erectile dysfunction), Men's Health Magazine.

Paul has worked for over 40 years in the design and implementation of nonqualified executive benefit plans for the ultra-affluent and corporate markets. Paul is a founding shareholder of The M Financial Group, one of the nation’s premier financial services design and distribution companies. From 2004 – 2018, he was a Managing Director and shareholder of Pen-Cal Administrators, a leading nonqualified plan financing and administration provider. Prior to his tenure with Pen-Cal, he was a Managing Director at another firm in this field for 25 years. Paul has been instrumental in the development and implementation of many innovative financing and investment techniques used in the benefits area, including the use of total return swaps and insurance wraps. Paul graduated with a B.S. degree in Business and Accounting from University of Southern California.

As an investment principal at the Bio Fund division of Taiwania Capital, Victoria actively invests in and manages Life Science, MedTech, and Bioinformatics investments, with a mission to cultivate bio-converging technologies that drive entrepreneurial innovation and address evidence-based unmet needs. She began her career in life science entrepreneurship and has held senior executive roles in craniomaxillofacial medical devices, CAD/CAM implant & restorative dentistry, imaging-based digital health, and healthcare management across the U.S., Europe, Taiwan, China, and the ASEAN region. Victoria holds an M.S. degree in Health Policy and Management from National Taiwan University and is currently pursuing graduate studies in Strategic Innovation and Global Strategy Management at the University of Illinois Urbana-Champaign.

With experience building innovative medical devices over two decades, Jon is a serial entrepreneur, leader, and advisor. Jon led the development of Prescient Surgical'sCleanCision technology from conception through commercial profitability, and recently led the development of a breast cancer innovation through a successful acquisition. Prior to launching Prescient Surgical as a Stanford Biodesign Innovation Fellow, Jon held a range of roles in engineering, marketing, and leadership within the surgical instrument divisions of Johnson & Johnson and Medtronic. Jon is an inventor on over 100 issued patents and has successfully launched five major products across surgery and surgical oncology. He also founded two interventional cardiology companies, Metavention and Gradient Therapeutics. Jon holds SB and MS degrees in Mechanical Engineering from MIT and Georgia Tech, respectively.

Guiting Lin, MD, PhD, is a Professor of Urology and Co-director of the Knuppe Molecular Urology Laboratory at the University of California, San Francisco (UCSF). Dr. Lin completed his medical training in Urologic Surgery at Peking University, China's leading medical school in Beijing, and pursued postdoctoral research at UCSF’s Department of Urology in 2001. A global pioneer in microenergy medicine(MEM) research, Dr. Lin focuses on the biological mechanisms and clinical applications of microenergy technologies, including Low-Intensity Extracorporeal Shock Wave Therapy (Li-ESWT) and Microenergy Acoustic Pulse (MAP). He is particularly noted for his work in mechanotransduction and stem cell regulation, areas where he has made significant contributions to their clinical applications. Dr. Lin has authored numerous highly-cited scientific papers and has received five international awards, including the 2002 Outstanding Young Researcher Award, the 2016 ISSM Zorgniotti-Newman Prize, and the 2021 WMSM Best of Best Award from the International Society for Sexual and Impotence Research. In addition to his research, Dr. Lin serves as editor-in-chief and associate editor for several journals, including Uroprecision and Sexual Medicine. His research, which has resulted in over 180 publications, primarily focuses on tissue-resident stem and progenitor cells and their application in microenergy medicine (MEM) for treating urological conditions such as urinary stress incontinence (SUI). His work emphasizes the activation and mechanisms of stem cells, utilizing Li-ESWT and MAP for advancements in regenerative medicine.

Blair has been working in administration and operations for over 20 years. Starting with an internship at a small investment firm while attending college, she has consistently worked with high level executives to assist them in the daily management of their companies while also growing their businesses. She has been employed by both large international firms and small start-ups. Assisting multiple executives, coordinating with retailers, managing calendars and scheduling, proofing contracts, arranging business travel, while also maintaining client files and accounts are evidence of her multitasking abilities.

Margie Bell has over 30 years experience in high technology finance in both public and private companies. She has been instrumental in establishing corporate cultures that allow for rapid controlled growth with a focus on value creation and strong team interaction. Margie has been a key driver in corporate financing activities and establishing strong corporate governance. Margie worked with Accretive Solutions providing CFO-level support to startup companies in a variety of industries and held full-time roles in Sr. Management at Xilinx and AMD during rapid growth phases of the companies. Margie has an MBA from Indiana University.